Tensive Controls, Inc.

Tensive Controls, Inc. is a late stage preclinical company, that has a first in class MC4R antagonist drug-like peptide (TCMCB07), with CNS anti-inflammatory effects. TCMCB07 addresses the unmet medical need for an effective anticachexia therapeutic for cancer, or other conditions in which peripheral proinflammatory cytokines directly or indirectly produce elevated levels of CNS cytokines and inflammation, as well as sickness behavior . In cancer patients, the presence of cachexia and sickness behavior is a limiting factor in the aggressiveness and efficacy of different forms of anticancer therapy. A logical extension of these finding is to diseases (e.g. infections or renal failure), with a similar pathophysiological presentation.